Palavras-chave
Fraturas atípicas do fêmur
Bisfosfonatos
Como Citar
Resumo
Introdução: Os bisfosfonatos evoluíram como a base para o tratamento da osteoporose, reduzindo a incidência de fraturas. Recentemente, várias publicações descreveram a ocorrência de fraturas de fêmur atípicas de baixa energia associadas ao uso de bifosfonatos. O objetivo deste estudo foi avaliar o tempo médio de cicatrização de fraturas atípicas de fêmur associadas ao tratamento com bifosfonatos em comparação com um grupo controle.
Materiais e métodos: Avaliamos retrospectivamente 34 mulheres (idade média de 74 anos) com fraturas atípicas; 16 deles haviam recebido bisfosfonatos por pelo menos cinco anos. Foram tratados entre 2006 e 2017 e estabilizados com haste cefalomedular. Este grupo foi comparado a um grupo controle com características semelhantes.
Resultados: Vinte e dois tiveram fraturas subtrocantéricas e 12 tiveram fraturas diafisárias. 14% daqueles que tomaram bifosfonatos e foram submetidos à cirurgia necessitaram de uma revisão em comparação com 5,5% do grupo de controle. O tempo médio de consolidação foi maior nos tratados com bifosfonatos (8,5 vs. 6 meses), com diferença estatisticamente significativa (p <0,001).
Conclusões:O benefício do tratamento com bisfosfonatos na prevenção de fraturas é maior do que o risco de fraturas atípicas; entretanto, é importante avaliar a relação risco-benefício de cada paciente no início e durante o tratamento, lembrando que, apesar disso, o tempo de cicatrização é maior.
Referências
Chrischilles EA, Dasbach EJ, Rubenstein LM, Cook JR, Tabor HK, Black DM; for the Fracture Intervention Trial Research Group. The effect of alendronate on fracture-related healthcare utilization and costs: The Fracture Intervention Trial. Osteoporos Int 2001;12:654-60. https://doi.org/10.1007/s001980170065 [ Links ]
Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52. https://doi.org/10.1001/jama.282.14.1344 [ Links ]
Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med 1998;338:485-92. https://doi.org/10.1056/NEJM199802193380801 [ Links ]
Karpf DB, Shapiro DR, Seeman E, Ensrud KE, Johnston CC Jr, Adami S, et al. Prevention of nonvertebral fractures by alendronate: a meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA 1997;277:1159-64. https://doi.org/10.1001/jama.1997.03540380073035 [ Links ]
Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-43. https://doi.org/10.1056/NEJM199511303332201 [ Links ]
Riggs BL, Melton LJ III. The prevention and treatment of osteoporosis. N Engl J Med 1992;327:620-7. https://doi.org/10.1056/NEJM199208273270908 [ Links ]
Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008;CD001155. https://doi.org/10.1002/14651858.CD001155.pub2 [ Links ]
Cao Y, Mori S, Mashiba T, Westmore MS, Ma L, Sato M, et al. Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res 2002;17:2237-46. https://doi.org/10.1359/jbmr.2002.17.12.2237 [ Links ]
Isaacs JD, Shidiak L, Harris IA, Szomor ZL. Femoral insufficiency fractures associated with prolonged bisphosphonate therapy. Clin Orthop Relat Res 2010;468:3384-92. https://doi.org/10.1007/s11999-010-1535-x [ Links ]
Mashiba T, Hui S, Turner CH, Mori S, Johnston CC, Burr DB. Bone remodeling at the iliac crest can predict the changes in remodeling dynamics, microdamage accumulation, and mechanical properties in the lumbar vertebrae of dogs. Calcif Tissue Int 2005;77:180-5. https://doi.org/10.1007/s00223-005-1295-x [ Links ]
Mashiba T, Mori S, Burr DB, Komatsubara S, Cao Y, Manabe T, Norimatsu H. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 2005;23(Suppl):36-42. https://doi.org/10.1007/BF03026321 [ Links ]
Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci 1999;96:133-8. https://doi.org/10.1073/pnas.96.1.133 [ Links ]
Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13:581-9. https://doi.org/10.1359/jbmr.1998.13.4.581 [ Links ]
Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-1301. https://doi.org/10.1210/jc.2004-0952 [ Links ]
Ahn JK, Lee J, Cha HS, Koh EM. Non-traumatic fracture of the femoral shaft in a patient taking long-term bisphosphonate therapy. Rheumatol Int 2011;31:973-5. https://doi.org/10.1007/s00296-010-1477-3 [ Links ]
Aspenberg P. Bisphosphonate-induced fractures: nature strikes back? Acta Orthop 2008;79:459-60. https://doi.org/10.1080/17453670710015427 [ Links ]
Goh S-K, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007;89:349-53. https://doi.org/10.1302/0301-620X.89B3.18146 [ Links ]
Chan SS, Rosenberg ZS, Chan K, Capeci C. Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: imaging features. AJR Am J Roentgenol 2010;194(6):1581-6. https://doi.org/10.2214/AJR.09.3588 [ Links ]
Weil YA, Rivkin G, Safran O, Liebergall M, Foldes AJ. The outcome of surgically treated femur fractures associated with long-term bisphosphonate use. J Trauma 2011;71(1):186-90. https://doi.org/10.1097/TA.0b013e31821957e3 [ Links ]
Egol KA, Park JH, Rosenberg ZS, Peck V, Tejwani NC. Healing delayed but generally reliable after bisphosphonateassociated complete femur fractures treated with IM nails. Clin Orthop Relat Res 2014;472(9):2728-34. https://doi.org/10.1007/s11999-013-2963-1 [ Links ]
Prasarn ML, Ahn J, Helfet DL, Lane JM, Lorich DG. Bisphosphonate-associated femur fractures have high complication rates with operative fixation. Clin Orthop Relat Res 2012;470(8):2295-301. https://doi.org/10.1007/s11999-012-2412-6 [ Links ]
Kang JS, Won YY, Kim JO, Min BW, Lee KH, Park KK, et al. Atypical femoral fractures after anti-osteoporotic medication: a Korean multicenter study. Int Orthop 2014;38(6):1247-53. https://doi.org/10.1007/s00264-013-2259-9 [ Links ]
Grady MK, Watson JT, Cannada LK. Treatment of femoral fracture nonunion after long-term bisphosphonate use. Orthopedics 2012;35(6):e991-5. https://doi.org/10.3928/01477447-20120525-51 [ Links ]
Sasaki S, Miyakoshi N, Hongo M, Kasukawa Y, Shimada Y. Low-energy diaphyseal femoral fractures associated with bisphosphonate use and severe curved femur: a case series. J Bone Miner Metab 2012;30(5):561-7. https://doi.org/10.1007/s00774-012-0358-0 [ Links ]
Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014;29(1):1-23. https://doi.org/10.1002/jbmr.1998 [ Links ]
Whelan DB, Bhandari M, McKee MD, Guyatt GH, Kreder HJ, Stephen D, et al. Interobserver and intraobserver variation in the assessment of the healing of tibial fractures after intramedullary fixation. J Bone Joint Surg Br 2002;84(1):15-8. https://doi.org/10.1302/0301-620x.84b1.11347 [ Links ]
Morris C, Einhorn T. Bisphosphonates in Orthopaedic Surgery. J Bone Joint Surg Am 2005;87:1609-618. https://doi.org/10.2106/JBJS.D.03032 [ Links ]
Gehrig L, Lane J, O’Connor M. Osteoporosis: management and treatment strategies for orthopaedic surgeons. J Bone Joint Surg Am 2008;90(6):1362-74. PMID: 18519332
Lyles K, Colón-Emeric C, Magaziner J, Adachi J, Pieper C. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-809. https://doi.org/10.1056/NEJMoa074941 [ Links ]
Capeci C, Tejwani N. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term Alendronate therapy. J Bone Joint Surg Am 2009;91:2556-61. https://doi.org/10.2106/JBJS.H.01774 [ Links ]
Puhaindran M, Farooki A, Steensma M, Hameed M, Healey J, Boland P. Atypical sub-trochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates. J Bone Joint Surg Am 2011;93:1235-42. https://doi.org/10.2106/JBJS.J.01199 [ Links ]
Rio M, Salonia P, Gabas D, Gotter G, Barrera Oro F. Fracturas de fémur asociadas al consumo prolongado de alendronato. Informe de dos casos. Rev Asoc Argent Ortop Traumatol 2011;76:74-76. http://www.scielo.org.ar/pdf/raaot/v76n1/v76n1a12.pdf [ Links ]
Fowler J, Criner K, Craig M. Prophylactic intramedullary fixation for bisphosphonate-related subtrochanteric stress fracture. Orthopedics 2012;35(6):e954-7. https://doi.org/10.3928/01477447-20120525-41 [ Links ]
Yoon R, Beebe K, Benevenia J. Prophylactic bilateral intramedullary femoral nails for bisphosphonate-associated signs of impending subtrochanteric hip fracture. Orthopedics 2010;33(4). https://doi.org/10.3928/01477447-20100225-21 [ Links ]
Banffy M, Vrahas M, Ready J, Abraham J. Nonoperative versus prophylactic treatment of bisphosphonateassociated femoral stress fractures. Clin Orthop Relat Res 2011;469(7):2028-34. https://doi.org/10.1007/s11999-011-1828-8 [ Links ]
Thompson RN, Phillips JR, McCauley SH, Elliott JR, Moran CG. Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals. J Bone Joint Surg Br 2012;94(3):385-90. https://doi.org/10.1302/0301-620X.94B3.27999 [ Links ]
Unnanuntana A, Saleh A, Mensah KA, Kleimeyer JP, Lane JM. Atypical femoral fractures: what do we know about them? AAOS Exhibit Selection. J Bone Joint Surg Am 2013;95:e8(1-13). https://doi.org/10.2106/JBJS.L.00568 [ Links ]
Issack PS. Bisphosphonate-associated subtrochanteric femoral fracture with profound proximal cortical thickening and canal narrowing requiring blade-plate fixation. A report of two cases. J Bone Joint Surg Case Connect 2014;24:e87. https://doi.org/10.2106/JBJS.CC.N.00026 [ Links ]
Shane E, Burr D, Ebling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25:2267-94. https://doi.org/10.1002/jbmr.253 [ Links ]
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Copyright (c) 2020 Cassio Mendes Cunha , Elzebio Marques Bandeira, Maria Claudia Maia Juares
